作者
Juan M Jimenez-Vacas, Daniel Westaby, Ines Figueiredo, Jan Rekowski, Claire Pettinger, Bora Gurel, Denisa Bogdan, Lorenzo Buroni, Antje Neeb, Ana Padilha, Joe Taylor, Wanting Zeng, Souvik Das, Emily Hobern, Ruth Riisnaes, Mateus Crespo, Susana Miranda, Ana Ferreira, Brian Hanratty, Rodrigues Daniel Nava, Claudia Bertan, George Seed, Christina Guo, Juliet Carmichael, Rafael Grochot, Khobe Chandran, Anastasia Stavridi, Andreas Varkaris, Nataly Stylianou, Brett Hollier, Nina Tunariu, Steven Balk, Suzanne Carreira, Wei Yuan, Peter Nelson, Eva Corey, Michael Haffner, Adam Sharp
发表日期
2024/5/6
期刊
Endocrine Abstracts
卷号
99
出版商
Bioscientifica
简介
Background: Treatment resistance in prostate cancer can be the result of multiple different tumour cell adaptations generating castration-resistant prostate cancer (CRPC). Despite advancements in treatment, CRPC remains a highly lethal disease. Some CRPCs become AR independent with loss of AR expression and lineage plasticity, urgently requiring novel therapeutic strategies. BCL2 can be upregulated in some CRPCs and may be a therapeutic target for this disease subset.
Objective: To characterise BCL2 expression in late stage CRPC, determine its association with AR expression, uncover its mechanisms of regulation, elucidate their clinical significance, and evaluate BCL2 as a therapeutic target and/or biomarker with clinical utility.
Methods: AR and BCL2 protein expression were determined by immunohistochemistry (IHC) in two separate CRPC cohorts. IHC data were correlated with clinical outcomes …
学术搜索中的文章
JM Jimenez-Vacas, D Westaby, I Figueiredo… - Endocrine Abstracts, 2024